Patents by Inventor Neil John Press

Neil John Press has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES
    Publication number: 20200277378
    Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 3, 2020
    Inventors: Catherine Anne Sabatos-Peyton, Jennifer Marie Mataraza, Kenzie MacIsaac, Eunice Kwak, Jason Faris, Glenn Dranoff, Marion Wiesmann, Fiona Sharp, Adam Crystal, John Scott Cameron, Robert Martin Strieter, Lilli Petruzzelli, Shamsah Kazani, David Andrew Sandham, Neil John Press, Keith Hoffmaster
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 9115087
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: August 25, 2015
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • ORGANIC COMPOUNDS
    Publication number: 20140213594
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: April 1, 2014
    Publication date: July 31, 2014
    Applicant: NOVARTIS AG
    Inventors: Urs BAETTIG, Anne-Marie D'SOUZA, Peter HUNT, Neil John PRESS, Simon James WATSON
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 8722925
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 13, 2014
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'souza, Peter Hunt, Neil John Press, Simon James Watson
  • ORGANIC COMPOUNDS
    Publication number: 20130005735
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Inventors: Urs Baettig, Anne-Marie D'souza, Peter Hunt, Neil John Press, Simon James Watson
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 8329754
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: December 11, 2012
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 8288588
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: October 16, 2012
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'souza, Peter Hunt, Neil John Press, Simon James Watson
  • CXC-chemokine receptor ligands
    Patent number: 8183281
    Abstract: The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: May 22, 2012
    Assignee: Novartis AG
    Inventors: Neil John Press, Simon James Watson
  • Quaternary ammonium salts as M3 antagonists
    Patent number: 8153669
    Abstract: Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: April 10, 2012
    Assignee: Novartis AG
    Inventors: Neil John Press, Stephen Paul Collingwood
  • SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST
    Publication number: 20110251205
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • Squaramide derivatives as CXCR2 antagonist
    Publication number: 20110251206
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 7989497
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2
    Publication number: 20110009429
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, X, Y and Z are as defined in the specification.
    Type: Application
    Filed: February 25, 2009
    Publication date: January 13, 2011
    Inventors: Paul Oakley, Neil John Press, Carsten Spanka, Simon James Watson
  • QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
    Publication number: 20100168132
    Abstract: Compounds of Formula (I) ; in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: March 11, 2010
    Publication date: July 1, 2010
    Inventors: Neil John Press, Stephen Paul Collingwood, Urs Baettig, Brian Cox, Sudhakar Devidasrao Garad, Hyungshul Kim, Dimitris Papoutsakis, Simon James Watson
  • Quinoline-2-one derivatives for the treatment of airways diseases
    Patent number: 7745462
    Abstract: Compounds of formula I in free or salt form, wherein —C—Y—, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the ?2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: June 29, 2010
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, David Andrew Sandham, David Beattie, Ian Bruce, Bernard Cuenoud, Reamonn Madden, Neil John Press, Roger John Taylor, Katharine Louise Turner, Simon James Watson
  • Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
    Patent number: 7723356
    Abstract: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: May 25, 2010
    Assignee: Novartis AG
    Inventors: Neil John Press, Stephen Paul Collingwood, Urs Baettig, Brian Cox, Sudhakar Devidasrao Garad, Hyungchul Kim, Dimitris Papoutsakis, Simon James Watson
  • CXC-CHEMOKINE RECEPTOR LIGANDS
    Publication number: 20100125071
    Abstract: The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof.
    Type: Application
    Filed: June 4, 2008
    Publication date: May 20, 2010
    Inventors: Neil John Press, Simon James Watson
  • CXCR2 inhibitors
    Publication number: 20100069407
    Abstract: The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.
    Type: Application
    Filed: November 21, 2007
    Publication date: March 18, 2010
    Inventors: Neil John Press, David Porter, Carsten Spanka
  • CXCR2 inhibitors
    Publication number: 20100063080
    Abstract: The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.
    Type: Application
    Filed: November 21, 2007
    Publication date: March 11, 2010
    Inventors: Neil John Press, Peter Hunt, David Porter, Diana Janus
  • ORGANIC COMPOUNDS
    Publication number: 20100029670
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: July 30, 2009
    Publication date: February 4, 2010
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson